Johnson & Johnson (JNJ) EPS Diluted: 11.03
Is Johnson & Johnson’s EPS diluted high or low?
Johnson & Johnson's EPS diluted of 11.03 is 31% above its 5-year average of 8.43, around the middle of its 5-year range (5.51–13.72).
31.15% above its 12-month average of 8.41.
JNJ EPS Diluted Chart
JNJ Average EPS Diluted Chart
JNJ Current vs Average EPS Diluted Chart
JNJ EPS Diluted Metrics
EPS DILUTED
11.03
EPS DILUTED AVG TTM
8.41
EPS DILUTED AVG 3Y
9.32
EPS DILUTED AVG 5Y
8.43
EPS DILUTED AVG 10Y
6.70
EPS DILUTED AVG 15Y
6.02
EPS DILUTED AVG 20Y
5.53
CURRENT VS TTM AVG
+31.15%
CURRENT VS 3Y AVG
+18.38%
CURRENT VS 5Y AVG
+30.82%
CURRENT VS 10Y AVG
+64.60%
CURRENT VS 15Y AVG
+83.17%
CURRENT VS 20Y AVG
+99.63%
Johnson & Johnson EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson EPS Diluted FAQ
- What is the EPS diluted for Johnson & Johnson (JNJ)?
- The EPS diluted for JNJ stock is 11.03.
- Is Johnson & Johnson's EPS diluted high or low?
- Johnson & Johnson's EPS diluted of 11.03 is 31% above its 5-year average of 8.43, around the middle of its 5-year range (5.51–13.72).
- What is the TTM average EPS diluted for Johnson & Johnson (JNJ)?
- The TTM average EPS diluted for JNJ stock is 8.41.
- What is the 3Y average EPS diluted for Johnson & Johnson (JNJ)?
- The 3Y average EPS diluted for JNJ stock is 9.32.
- What is the 5Y average EPS diluted for Johnson & Johnson (JNJ)?
- The 5Y average EPS diluted for JNJ stock is 8.43.
- What is the 10Y average EPS diluted for Johnson & Johnson (JNJ)?
- The 10Y average EPS diluted for JNJ stock is 6.70.
- What is the 15Y average EPS diluted for Johnson & Johnson (JNJ)?
- The 15Y average EPS diluted for JNJ stock is 6.02.
- What is the 20Y average EPS diluted for Johnson & Johnson (JNJ)?
- The 20Y average EPS diluted for JNJ stock is 5.53.
Johnson & Johnson EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-28 | 11.03 |
| 2024-12-29 | 5.79 |
| 2023-12-31 | 13.72 |
| 2023-01-01 | 6.73 |
| 2022-01-02 | 7.81 |
| 2021-01-03 | 5.51 |
| 2019-12-31 | 5.63 |
| 2018-12-31 | 5.61 |
| 2017-12-31 | 0.47 |
| 2016-12-31 | 5.93 |
| 2015-12-31 | 5.48 |
| 2014-12-31 | 5.70 |
| 2013-12-31 | 4.81 |
| 2012-12-31 | 3.86 |
| 2011-12-31 | 3.49 |
| 2010-12-31 | 4.78 |
| 2009-12-31 | 4.40 |
| 2008-12-31 | 4.57 |
| 2007-12-31 | 3.63 |
| 2006-12-31 | 3.73 |
| 2005-12-31 | 3.35 |
| 2004-12-31 | 2.74 |
| 2003-12-31 | 2.29 |
| 2002-12-31 | 2.16 |
| 2001-12-31 | 1.84 |
| 2000-12-31 | 1.61 |
| 1999-12-31 | 1.39 |
| 1998-12-31 | 1.06 |
| 1997-12-31 | 1.21 |
| 1996-12-31 | 1.09 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato